Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsNeighborhood Health Plan Kygevvi Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

    Kygevvi Coverage for Thymidine Kinase 2 Deficiency

    Customize your policy alerts

    Sign up for all Neighborhood Health Plan of Rhode Island policy alerts

    Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for Kygevvi (doxecitine and doxribtimine) for Medicaid members with thymidine kinase 2 deficiency when stated approval criteria are met and no exclusions apply.

    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyKygevvi Coverage for Thymidine Kinase 2 Deficiency
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with required clinical documentation before treatment.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsAuthorization period
    ≤12 yearsSymptom onset
    800 mg/kg/dayMaximum daily dose
    Biallelic TK2 variantsGenetic confirmation
    Not covered

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Other indications

    Coverage Criteria

    Initial Therapy for TK2d

    Authorization of 6 months may be granted when all of the following criteria are met.

    Initial therapy for TK2d

    • Specialist prescribing: The medication is prescribed by or in consultation with a geneticist, neurologist, or specialist in the treatment of neuromuscular disorders.
    • Genetic confirmation: Documentation of genetic testing detects biallelic pathogenic variants in the thymidine kinase 2 (TK2) gene confirming the diagnosis of TK2d.Biallelic pathogenic TK2 variants
    • Early symptom onset: Documentation shows that initial symptoms, such as limb muscle weakness, respiratory weakness, loss of motor functions, or need for ventilatory support, began on or before 12 years of age.On or before 12 years of age
    • Liver function and disease history: Baseline ALT, AST, and total bilirubin are less than two times the laboratory upper limit of normal, and the member has no history of liver disease.ALT, AST, and total bilirubin <2 times the laboratory ULN
    • Other disease exclusions: Documentation confirms absence of other genetic disease, polygenic disease, or concurrent inborn error of metabolism.
    • Renal exclusion: The member does not have renal insufficiency requiring dialysis.
    • Cardiac and lactic acidosis exclusion: The member does not have severe end-organ hypoperfusion syndrome secondary to cardiac failure resulting in lactic acidosis.
    • Dose limit: Documentation shows that the prescribed dose does not exceed 800 mg/kg/day, consisting of 400 mg doxecitine and 400 mg doxribtimine. The member's current weight and prescribed dose must be provided.≤800 mg/kg/day total

    Continuation Therapy for TK2d

    Authorization of 6 months may be granted for continuation when all of the following criteria are met.

    Continuation therapy for TK2d

    • Prior Neighborhood approval

    • Positive clinical response: Chart notes and/or medical records document that the member has demonstrated a positive clinical response to therapy, such as improvement or stabilization in motor function, pulmonary function, ventilatory-support needs, or the ability to meet growth and developmental milestones.

      Examples include improvement or stabilization on the 6-minute walk test, Motor Function Measure 20 or 30, reduced reliance on ventilatory support, or achievement of sitting, standing, or walking milestones.

    • Dose limit: Documentation shows that the prescribed dose does not exceed 800 mg/kg/day, consisting of 400 mg doxecitine and 400 mg doxribtimine. The member's current weight and prescribed dose must be provided.≤800 mg/kg/day total

    Coverage is limited to Kygevvi for thymidine kinase 2 deficiency (TK2d). Indications other than treatment of TK2d are considered experimental/investigational and not medically necessary.

    Coverage criteria exclude members with a history of liver disease, other genetic or polygenic disease, or a concurrent inborn error of metabolism. The criteria also exclude members with renal insufficiency requiring dialysis or severe end-organ hypoperfusion syndrome secondary to cardiac failure resulting in lactic acidosis.

    All indications other than the FDA-approved treatment of thymidine kinase 2 deficiency are considered experimental/investigational and not medically necessary.

    Clinical and Quantity Parameters

    Age at symptom onset
    Eligible patientsAdults and pediatric patients with symptom onset on or before 12 years of age
    Maximum age at symptom onset12 years
    Covered conditionThymidine kinase 2 deficiency (TK2d)
    Baseline liver function tests
    ALTLess than two times the laboratory upper limit of normal
    ASTLess than two times the laboratory upper limit of normal
    Total bilirubinLess than two times the laboratory upper limit of normal

    Authorization and Documentation Requirements

    Prior Authorization

    Six-Month Prior Authorization

    Prior authorization is required for Kygevvi. When coverage criteria are met, both initial and continuation authorization periods are limited to 6 months.

    Documentation Required

    Specialist Prescriber Required

    Kygevvi must be prescribed by, or prescribed in consultation with, a geneticist, neurologist, or specialist in the treatment of neuromuscular disorders.

    Documentation Required

    Initial Clinical Documentation

    For initial authorization, submit documentation supporting the diagnosis, eligibility, safety, and prescribed dose. The submission must include the prescribing clinician or specialist consultant, genetic testing confirming TK2d, symptom-onset history, laboratory results, relevant disease history, and current weight with the prescribed dose.

    Policy Background

    Kygevvi is covered for adults and pediatric patients with thymidine kinase 2 deficiency when initial symptoms began on or before 12 years of age. Coverage is subject to the policy’s genetic confirmation, laboratory, disease-exclusion, dose, and authorization requirements.

    Key Definition

    Thymidine kinase 2 deficiency (TK2d)
    ConditionThymidine kinase 2 deficiency (TK2d)
    Genetic confirmationTesting detects biallelic pathogenic variants
    GeneThymidine kinase 2 (TK2) gene

    Initial Kygevvi Approval

    Initial Kygevvi Approval

    Authorization of 6 months may be granted for treatment of TK2d when all of the following criteria are met.

    Initial Kygevvi therapy

    • Specialist prescribing: The medication is prescribed by or in consultation with a geneticist, neurologist, or specialist in the treatment of neuromuscular disorders.
    • Genetic confirmation: Documentation of genetic testing detects biallelic pathogenic variants in the thymidine kinase 2 (TK2) gene confirming the diagnosis of TK2d.Biallelic pathogenic TK2 variants
    • Early symptom onset: Documentation shows that initial symptoms, such as limb muscle weakness, respiratory weakness, loss of motor functions, or need for ventilatory support, began on or before 12 years of age.

    Continuation of Kygevvi

    Continuation of Kygevvi

    Authorization of 6 months may be granted for continued treatment when all applicable criteria are met.

    • Prior Neighborhood approval

    • Positive clinical response: Chart notes and/or medical records document that the member has demonstrated a positive clinical response to therapy, such as improvement or stabilization in motor function, pulmonary function, ventilatory-support needs, or the ability to meet growth and developmental milestones.

      Examples include improvement or stabilization on the 6-minute walk test, Motor Function Measure 20 or 30, reduced reliance on ventilatory support, or achievement of sitting, standing, or walking milestones.

    • Dose limit: Documentation shows that the prescribed dose does not exceed 800 mg/kg/day, consisting of 400 mg doxecitine and 400 mg doxribtimine. The member's current weight and prescribed dose must be provided.≤800 mg/kg/day total

    Kygevvi Dose Limit

    Kygevvi quantity limit
    MedicationKygevvi (doxecitine and doxribtimine)
    Maximum total daily dose800 mg/kg/day total
    Dose components400 mg doxecitine and 400 mg doxribtimine
    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyKygevvi Coverage for Thymidine Kinase 2 Deficiency
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with required clinical documentation before treatment.
    SourceLink
    On This Page
    Coverage CriteriaClinical and Quantity ParametersAuthorization and Documentation RequirementsPolicy BackgroundKey DefinitionInitial Kygevvi ApprovalContinuation of KygevviKygevvi Dose Limit
    Maximum Kygevvi dose
    Maximum total dose800 mg/kg/day
    Doxecitine component400 mg/kg/day
    Doxribtimine component400 mg/kg/day
    • Genetic testing must detect biallelic pathogenic variants in the TK2 gene.
    • Document initial symptom onset on or before 12 years of age, including relevant motor or respiratory symptoms.
    • Provide baseline ALT, AST, and total bilirubin results, each less than two times the laboratory's upper limit of normal.
    • Document absence of liver disease, other genetic or polygenic disease, and concurrent inborn error of metabolism.
    • Document that the member does not have renal insufficiency requiring dialysis or severe end-organ hypoperfusion syndrome secondary to cardiac failure resulting in lactic acidosis.
    • Provide the member's current weight and prescribed dose; the dose must not exceed 800 mg/kg/day, consisting of 400 mg doxecitine and 400 mg doxribtimine.
    Documentation Required

    Continuation Documentation

    For continuation authorization, submit chart notes and/or medical records demonstrating that the member has had a positive clinical response to therapy. If Neighborhood has not previously approved the drug, also submit documentation showing that the initial criteria are met.

    • Examples of positive response include improvement or stabilization in motor function, such as 6-minute walk test (6MWT), Motor Function Measure (MFM) 20 or MFM 30; reduced reliance on ventilatory support; or ability to meet growth and developmental milestones.
    • Provide the member's current weight and prescribed dose; the dose must not exceed 800 mg/kg/day, consisting of 400 mg doxecitine and 400 mg doxribtimine.
    Denial Risk

    Noncovered Indications

    Uses other than the FDA-approved treatment of thymidine kinase 2 deficiency (TK2d) are not covered and are considered experimental/investigational and not medically necessary.

    Denial Risk

    Initial Criteria Not Met

    Initial authorization may be denied when required specialty, diagnostic, clinical, laboratory, or disease-history criteria are not documented or are not met.

    • The prescription is not by or in consultation with a geneticist, neurologist, or neuromuscular disease specialist.
    • Genetic testing does not confirm TK2d through biallelic pathogenic variants in the TK2 gene.
    • Initial symptom onset was after 12 years of age.
    • Baseline ALT, AST, or total bilirubin is two or more times the laboratory's upper limit of normal, or the member has a history of liver disease.
    • The member has another genetic or polygenic disease, a concurrent inborn error of metabolism, renal insufficiency requiring dialysis, or severe end-organ hypoperfusion syndrome secondary to cardiac failure resulting in lactic acidosis.
    • The prescribed dose exceeds 800 mg/kg/day, or the member's current weight and prescribed dose are not provided.
    Denial Risk

    Continuation Criteria Not Met

    Continuation authorization may be denied when required prior-approval documentation, evidence of positive clinical response, or current dosing information is absent or does not meet criteria.

    • If Neighborhood has not previously approved Kygevvi, documentation that the initial criteria are met is not submitted.
    • Chart notes or medical records do not demonstrate a positive clinical response to therapy.
    • The prescribed dose exceeds 800 mg/kg/day, or the member's current weight and prescribed dose are not provided.
    On or before 12 years of age
  1. Liver function and disease history: Baseline ALT, AST, and total bilirubin are less than two times the laboratory upper limit of normal, and the member has no history of liver disease.ALT, AST, and total bilirubin <2 times the laboratory ULN
  2. Other disease exclusions: Documentation confirms absence of other genetic disease, polygenic disease, or concurrent inborn error of metabolism.
  3. Renal exclusion: The member does not have renal insufficiency requiring dialysis.
  4. Cardiac and lactic acidosis exclusion: The member does not have severe end-organ hypoperfusion syndrome secondary to cardiac failure resulting in lactic acidosis.
  5. Dose limit: Documentation shows that the prescribed dose does not exceed 800 mg/kg/day, consisting of 400 mg doxecitine and 400 mg doxribtimine. The member's current weight and prescribed dose must be provided.≤800 mg/kg/day total